Gastrointestinal Stromal Tumors II: Medical Oncology and Tumor Response AssessmentDisclosures
Section snippets
State-of-the-Art Tumor Response Assessment
It is clear that patients with gastrointestinal stromal tumors (GIST) do not play by the rules as pertains to response assessment after treatment with tyrosine kinase inhibitors (TKIs). What appeared to be new disease in the liver was actually responding disease that became hypodense after TKIs. Similarly, clear disease progression on imatinib with the “tumor within a tumor” effect is a finding not captured by either Response Evaluation Criteria in Solid Tumors (RECIST) or World Health
Primary and Secondary Resistance to Imatinib
Resistance to imatinib mesylate is a growing clinical problem in the management of GIST. Primary resistance is defined as evidence of clinical progression developing during the first 6 months of TKI treatment. Primary resistance is most commonly seen in patients with tumors carrying mutations in KIT exon 9 or in PDGFRA exon 18, or with tumors that are wild type for both genes.12, 13 Based on in vitro studies, the most common PDGFRA mutation, D842V substitution, which confers primary resistance
Delivering Treatment: Dose Intensity and Dose Density
As we reach the end of the first decade of the use of imatinib for patients with GIST (the first patient with GIST being treated with imatinib in March 2000),25 it is worthwhile reviewing the dosing of this remarkable drug. Specifically, given the use of scaled dosing of most chemotherapy agents, ie, dosing by body surface area or by weight, and the widespread use of weight-based dosing of medications in the pediatric setting, why is a flat dose of imatinib typically given to GIST patients (ie,
Delivering Treatment: Pharmacology-Driven Therapy
As holds true for all drugs that are orally administered, the pharmacokinetics of imatinib are largely determined by the absorption of the drug, the binding to blood components, its metabolism, and its elimination. With respect to absorption, imatinib has an excellent bioavailability, exceeding 95%, which is unaffected by food intake.42 It is thought that ATP-binding cassettes (ABC) pumps such as p-glycoprotein and breast cancer resistance (BCR) protein can influence the absorption of imatinib.
New Avenues in Gist Treatment
A variety of questions remain active issues for patients with recurrent GIST. Since only imatinib has been tested as first-line therapy in patients with metastatic GIST, we do not yet know the “best” first-line agent for this clinical situation. We are increasingly trying to target patients' therapies based on the clinical and genetic characteristics of their tumors. We are searching for ways to maximize the benefit from the drugs we have at hand presently. We do not know how best to treat
Where are We, in the End?
The management of GIST has improved during the past decade with a rapidity that rivals virtually any other type of human cancer. Yet, a majority of patients diagnosed with advanced GIST are still not cured with the currently available therapies.10, 26, 29 Therefore, new treatment options need to be explored.
A large group of novel TKIs related to imatinib and sunitinib are currently under clinical evaluation or recently evaluated. Several of these agents are listed in Table 1. Some of these have
References (61)
- et al.
Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs)
Eur J Cancer
(2002) - et al.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eur J Cancer
(2009) - et al.
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
Eur J Cancer
(2004) - et al.
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants
Gastroenterology
(2005) - et al.
Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations
Lancet Oncol
(2005) - et al.
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
Lancet
(2001) - et al.
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
Lancet
(2004) - et al.
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular targetResults from an EORTC Soft Tissue and Bone Sarcoma Group phase II study
Eur J Cancer
(2003) - et al.
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
Blood
(2008) - et al.
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels
Leuk Res
(2009)
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
Eur J Cancer
Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor
Cell
Targeting Hsp90: small-molecule inhibitors and their clinical development
Curr Opin Pharmacol
Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate
Ann Oncol
Meaningful clinical classification of therapeutic responses to anticancer drugs
Clin Pharmacol Ther
Reporting results of cancer treatment
Cancer
WHO handbook for reporting results of cancer treatmentOffset publication No. 48
The effect of measuring error on the results of therapeutic trials in advanced cancer
Cancer
New guidelines to evaluate the response to treatment in solid tumorsEuropean Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
J Natl Cancer Inst
Who took the clinical out of clinical research?—Mouse versus man: seventh David A Karnofsky Memorial Lecture—1976
Clin Cancer Res
We should desist using RECIST, at least in GIST
J Clin Oncol
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria
J Clin Oncol
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
J Clin Oncol
PDGFRA activating mutations in gastrointestinal stromal tumors
Science
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib
J Clin Oncol
Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation
Clin Cancer Res
Sunitinib treatment of pediatric metastatic GIST after failure of imatinib [abstract]
J Clin Oncol
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
Clin Cancer Res
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
J Clin Oncol
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor
Clin Cancer Res
Cited by (34)
Imaging surveillance of gastrointestinal stromal tumour: current recommendation by National Comprehensive Cancer Network and European Society of Medical Oncology-European Reference Network for rare adult solid cancers
2019, Clinical RadiologyCitation Excerpt :Resistance to treatment with imatinib can be primary or secondary. Primary resistance to imatinib occurs in the first 6 months of therapy and encountered in GISTs with KIT exon 9, PDGFRA exon 18, SDH-deficient and wild-type GISTs.46 Primary resistance to treatment is suspected on imaging when there are no typical density changes or decline in metabolic activity on the first restaging CT or PET/CT.
A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis
2013, HPBCitation Excerpt :After initiation of therapy, patients are assessed at short intervals to determine therapeutic effect. Non‐responders, especially those with documented mutations in KIT exon 9, may benefit from dose escalation[4-6] of imatinib mesylate depending upon clinical tolerance, whereas others may benefit from approved second‐line therapy with sunitinib malate.[7] This approach of preoperative TKI therapy followed by resection in patients with localized disease is based on observations of different investigators: patients with stable or responsive tumours achieved 12‐month overall survival (OS) of 95% in one study[8] and 2‐year actuarial survival approaching 100% in another.[9]
Resistance to treatment in gastrointestinal stromal tumours: What radiologists should know
2013, Clinical RadiologyCitation Excerpt :Imatinib has dramatic efficacy in advanced GIST and was approved by the United States Food and Drug Administration (US FDA) and European Union in 2002 as the first line of treatment in patients with such tumours. Nevertheless, a subset of GISTs are inherently resistant to imatinib as they harbour different kinds of mutations.3 Additionally, GISTs may develop secondary resistance to imatinib during the course of treatment.4
Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors
2012, Journal of Surgical ResearchCitation Excerpt :However, not all GISTs respond to TKI therapy, and approximately 20% of patients do not tolerate specific TKI agents [2,9,10]. In addition, different exon mutations, wild-type status, and the development of tumor mutations during therapy can result in treatment resistance to TKIs [2,11,12]. Resection remains an option for patients with metastatic GIST.
- Disclosures
R.S. Benjamin: Novartis (consulting, speaker's bureau)
M. Debiec-Rychter: Novartis (research support)
A. Le Cesne: Novartis (honoraria)
S. Sleijfer: Pfizer, Novartis (research support)
G.D. Demetri: Novartis, Pfizer, Ariad, Johnson & Johnson, Genentech, Plexxikon, Bristol Meyers Squibb Research, Infinity Pharmaceuticals, Ziopharm, Alnylam, Idera, Bayer, Serono, Amgen (research support, consulting)
H. Joensuu: Novartis, Bayer-Schering Pharma (honoraria), testimony (Pfizer)
P. Schöffski: Novartis (research funding and honoraria); Pfizer (research funding and honoraria)
A. Poveda: none
- 1,2
These authors contributed equally to this work.